The Prevalence of Metabolic Syndrome In Chronic Obstructive Pulmonary Disease: A Systematic Review

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 13, Issue 3, 2016, Pages 399-406

  Cebron Lipovec, Nanca ^a,b   Beijers, Rosanne J H C G ^a   van den Borst, Bram ^a   Doehner, Wolfram ^c   Lainscak, Mitja ^d,e   Schols, Annemie M W J ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b University Clinic of Pulmonary and Allergic Diseases Golnik   (Slovenia)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d General Hospital Celje   (Slovenia)

^e UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Co morbidities; components; lifestyle; prevalence

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; STATIN (PROTEIN); STEROID; TRIACYLGLYCEROL;

ABDOMINAL OBESITY; AGE; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; FORCED EXPIRATORY VOLUME; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INFLAMMATION; LIFESTYLE; METABOLIC SYNDROME X; PHARMACEUTICAL CARE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; SEX DIFFERENCE; SMOKING; STEROID THERAPY; SYSTEMATIC REVIEW; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; ARTERIAL PRESSURE; COMORBIDITY; PATHOPHYSIOLOGY; PREVALENCE;

ARTERIAL PRESSURE; BODY MASS INDEX; COMORBIDITY; FORCED EXPIRATORY VOLUME; HUMANS; HYPERGLYCEMIA; HYPERTENSION; METABOLIC SYNDROME; OBESITY, ABDOMINAL; PREVALENCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEX FACTORS;

EID: 84959045378     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.3109/15412555.2016.1140732     Document Type: Review

References (50)

1. C.D.Mathers, D.Loncar. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006; 3(11):e442.
2. A.Agusti, P.M.Calverley, B.Celli, H.O.Coxson, L.D.Edwards, D.A.Lomas, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010; 11:122.
3. J.Vestbo, S.S.Hurd, A.G.Agusti, P.W.Jones, C.Vogelmeier, A.Anzueto, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease GOLD executive summary. Am J Respir Crit Care Med 2013; 187(4):347–65.
4. D.M.Mannino, D.Thorn, A.Swensen, F.Holguin. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 2008; 32(4):962–9.
5. A.R.Patel, J.R.Hurst. Extrapulmonary comorbidities in chronic obstructive pulmonary disease: state of the art. Expert Rev Respir Med 2011; 5(5):647–62.
6. B.Xi, D.He, Y.Hu, D.Zhou. Prevalence of metabolic syndrome and its influencing factors among the Chinese adults: the China Health and Nutrition Survey in 2009. Prev Med 2013; 57(6):867–71.
7. S.Suh, M.K.Lee. Metabolic syndrome and cardiovascular diseases in Korea. J Atheroscler Thromb 2014; 21 Suppl 1:S31–5.
8. R.B.Ervin Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity, and body mass index: United States, 2003–2006. Natl Health Stat Rept 2009; (13):1–7.
9. E.Kassi, P.Pervanidou, G.Kaltsas, G.Chrousos. Metabolic syndrome: definitions and controversies. BMC Med 2011; 9:48.
10. S.N.Slagter, J.V.van Vliet-Ostaptchouk, J.M.Vonk, H.M.Boezen, R.P.Dullaart, A.C.Kobold, et al. Associations between smoking, components of metabolic syndrome and lipoprotein particle size. BMC Med 2013; 11:195.
11. K.Sun, J.Liu, G.Ning. Active smoking and risk of metabolic syndrome: a meta-analysis of prospective studies. PLoS One 2012; 7(10):e47791.
12. A.Bankoski, T.B.Harris, J.J.McClain, R.J.Brychta, P.Caserotti, K.Y.Chen, et al. Sedentary activity associated with metabolic syndrome independent of physical activity. Diabetes Care 2011; 34(2):497–503.
13. E.S.Ford, H.W.Kohl, M.A.H.3rd, Mokdad AH, U.A.Ajani. Sedentary behavior, physical activity, and the metabolic syndrome among U.S. adults. Obes Res 2005; 13(3):608–14.
14. C.E.Wells, E.H.Baker, Metabolic syndrome and diabetes mellitus in COPD. European Respiratory Monograph. 2013; 59:117–34.
15. K.G.Alberti, P.Z.Zimmet. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15(7):539–53.
16. B.Balkau, M.A.Charles. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999;16(5):442–3.
17. Expert Panel Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001; 285(19):2486–97.
18. S.M.Grundy, J.I.Cleeman, S.R.Daniels, K.A.Donato, R.H.Eckel, B.A.Franklin, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112(17):2735–52.
19. D.Einhorn, G.M.Reaven, R.H.Cobin, E.Ford, O.P.Ganda, Y.Handelsman, et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 2003; 9(3):237–52.
20. K.G.Alberti, P.Zimmet, J.Shaw. Metabolic syndrome–a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006; 23(5):469–80.
21. K.G.Alberti, R.H.Eckel, S.M.Grundy, P.Z.Zimmet, J.I.Cleeman, K.A.Donato, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120(16):1640–5.
22. D.Moher, A.Liberati, J.Tetzlaff, D.G.Altman. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6(7):e1000097.
23. K.Marquis, F.Maltais, V.Duguay, A.M.Bezeau, P.LeBlanc, J.Jobin, et al. The metabolic syndrome in patients with chronic obstructive pulmonary disease. J Cardiopulm Rehabil 2005; 25(4):226–32.
24. S.K.Park, J.L.Larson. The relationship between physical activity and metabolic syndrome in people with chronic obstructive pulmonary disease. J Cardiovasc Nurs 2014; 29(6):499–507.
25. S.K.Park, J.L.Larson. Metabolic syndrome and associated factors in people with chronic obstructive pulmonary disease. West J Nurs Res. 2014; 36(5):620–42.
26. M.Poulain, M.Doucet, V.Drapeau, G.Fournier, A.Tremblay, P.Poirier, et al. Metabolic and inflammatory profile in obese patients with chronic obstructive pulmonary disease. Chron Respir Dis 2008; 5(1):35–41.
27. S.E.Tanni, A.T.S.Zamuner, L.S.Coelho, S.A.Vale, I.Godoy, S.A.R.Paiva. Are metabolic syndrome and its components associated with 5-year mortality in chronic obstructive pupmonary disease patients? Metab Syndr Relat Disord 2015; 13(1):52–4.
28. J.Diez-Manglano, J.Barquero-Romero, P.Almagro, F.J.Cabrera, F.Lopez Garcia, L.Montero, et al. COPD patients with and without metabolic syndrome: clinical and functional differences. Intern Emerg Med 2014; 9(4):419–25.
29. M.Minas, K.Kostikas, A.I.Papaioannou, P.Mystridou, E.Karetsi, P.Georgoulias, et al. The association of metabolic syndrome with adipose tissue hormones and insulin resistance in patients with COPD without co-morbidities. COPD 2011; 8(6):414–20.
30. M.K.Breyer, M.A.Spruit, C.K.Hanson, F.M.Franssen, L.E.Vanfleteren, M.T.Groenen, et al. Prevalence of metabolic syndrome in COPD patients and its consequences. PLoS One 2014; 9(6):e98013.
31. H.Watz, B.Waschki, A.Kirsten, K.C.Muller, G.Kretschmar, T.Meyer, et al. The metabolic syndrome in patients with chronic bronchitis and COPD: frequency and associated consequences for systemic inflammation and physical inactivity. Chest 2009; 136(4):1039–46.
32. G.Fumagalli, F.Fabiani, S.Forte, M.Napolitano, P.Marinelli, P.Palange, et al. INDACO project: a pilot study on incidence of comorbidities in COPD patients referred to pneumology units. Multidiscip Respir Med 2013; 8(1):28.
33. P.Skyba, J.Ukropec, P.Pobeha, B.Ukropcova, P.Joppa, T.Kurdiova, et al. Metabolic phenotype and adipose tissue inflammation in patients with chronic obstructive pulmonary disease. Mediators Inflamm 2010; 2010:173498.
34. E.E.Akpinar, S.Akpinar, S.Ertek, E.Sayin, M.Gulhan. Systemic inflammation and metabolic syndrome in stable COPD patients. Tuberk Toraks 2012; 60(3):230–7.
35. E.Kupeli, G.Ulubay, S.S.Ulasli, T.Sahin, Z.Erayman, A.Gursoy. Metabolic Syndrome is associated with increased risk of acute exacerbation of Chronic Obstructive Pulmonary Disease: A preliminary study. Chest 2010; 38(1):76–82.
36. A.Ozgen Alpaydin, I.Konyar Arslan, S.Serter, A.Sakar Coskun, P.Celik, F.Taneli, et al. Metabolic syndrome and carotid intima-media thickness in chronic obstructive pulmonary disease. Multidiscip Respir Med 2013; 8(1):61.
37. H.Hosny, H.Abdel-Hafiz, H.Moussa, A.Soliman. Metabolic syndrome and systemic inflammation in patients with chronic obstructive pulmonary disease. Egypt J Chest Dis Tuberc 2013; 62(1):85–9.
38. B.H.Park, M.S.Park, J.Chang, S.K.Kim, Y.A.Kang, J.Y.Jung, et al. Chronic obstructive pulmonary disease and metabolic syndrome: a nationwide survey in Korea. Int J Tuberc Lung Dis 2012; 16(5):694–700.
39. K.B.Lam, R.E.Jordan, C.Q.Jiang, G.N.Thomas, M.R.Miller, W.S.Zhang, et al. Airflow obstruction and metabolic syndrome: the Guangzhou Biobank Cohort Study. Eur Respir J 2010; 35(2):317–23.
40. Y.Funakoshi, H.Omori, S.Mihara, T.Marubayashi, T.Katoh. Association between airflow obstruction and the metabolic syndrome or its components in Japanese men. Intern Med 2010; 49(19):2093–9.
41. J.H.Chung, H.J.Hwang, C.H.Han, B.S.Son, D.H.Kim, M.S.Park. Association between sarcopenia and metabolic syndrome in chronic obstructive pulmonary disease: The Korea National Health and Nutrition Examination Survey (KNHANES) from 2008 to 2011. COPD 2015; 12(1):82–9.
42. J.Diez-Manglano, J.Barquero-Romero, P.Almagro, F.J.Cabrera, F.Lopez Garcia, L.Montero, et al. COPD patients with and without metabolic syndrome: clinical and functional differences. Intern Emerg Med 2014; 9(4):419–25.
43. P.R.Burgel, J.L.Paillasseur, B.Peene, D.Dusser, N.Roche, J.Coolen, et al. Two distinct chronic obstructive pulmonary disease (COPD) phenotypes are associated with high risk of mortality. PLoS One 2012; 7(12):e51048.
44. L.E.Vanfleteren, M.A.Spruit, M.Groenen, S.Gaffron, V.P.van Empel, P.L.Bruijnzeel, et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 187(7):728–35.
45. A.M.Schols, R.Broekhuizen, C.A.Weling-Scheepers, E.F.Wouters. Body composition and mortality in chronic obstructive pulmonary disease. Am J Clin Nutr 2005; 82(1):53–9.
46. C.van de Bool, C.Mattijssen-Verdonschot, P.P.van Melick, M.A.Spruit, F.M.Franssen, E.F.Wouters, et al. Quality of dietary intake in relation to body composition in patients with chronic obstructive pulmonary disease eligible for pulmonary rehabilitation. Eur J Clin Nutr 2014; 68(2):159–65.
47. K.G.Saag, D.E.Furst. 29 July 2014. Major side effects of systemic glucocorticoids. Available from: http://www.uptodate.com (accessed: 03July, 2015).
48. S.Khoza, J.C.Barner. Glucose dysregulation associated with antidepressant agents: an analysis of 17 published case reports. Int J Clin Pharm 2011; 33(3):484–92.
49. R.Kahn, J.Buse, E.Ferrannini, M.Stern, American Diabetes, European Association for the Study of Diabetes. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005; 28(9):2289–304.
50. C.K.Roberts, A.L.Hevener, R.J.Barnard. Metabolic syndrome and insulin resistance: underlying causes and modification by exercise training. Compr Physiol 2013; 3(1):1–58.